Hyperuricemia Potentiates Acute Pancreatitis via CNR1-Driven Inflammatory Cascades and Gut-Pancreas Axis Disruption: Molecular Insights and Sex-Dimorphic Implications

Abstract

Acute pancreatitis (AP) is a severe gastrointestinal condition characterized by unpredictable systemic inflammatory surges and high morbidity. Recent multi-omics paradigms identify hyperuricemia as a critical metabolic aggravator of AP severity, operating primarily through Cannabinoid Receptor 1 (CNR1) signaling and gut-pancreas axis dysregulation. Elevated soluble serum urate promotes intracellular reactive oxygen species (ROS) accumulation and mitochondrial dysfunction within pancreatic acinar cells, upregulating CNR1 expression and activating downstream NF-κB and NLRP3 inflammasome pathways. Systemically, hyperuricemia compromises intestinal mucosal barrier integrity by suppressing tight junction proteins (ZO-1 and Occludin), instigating gut dysbiosis and luminal lipopolysaccharide (LPS) translocation into the portal circulation. Crucially, sex-and-gender-based analysis (SGBA) reveals significant sexual dimorphism in these mechanistic pathways. Estrogen signaling modulates renal urate transporters (SLC2A9/URAT1) to maintain lower baseline urate levels and dampens pro-inflammatory endocannabinoid activity in females. This review elucidates the molecular circuitry bridging hyperuricemia, CNR1, and the gut-pancreas axis while discussing sex-informed precision therapeutics for AP management.

Introduction & Cellular Mechanisms

Acute pancreatitis (AP) progresses from localized acinar cell injury to systemic inflammatory response syndrome (SIRS) and multi-organ dysfunction. While gallstones and alcohol abuse remain primary etiologies, metabolic dysregulation—specifically hyperuricemia—has emerged as a major modifier of disease trajectory. Soluble uric acid (UA), traditionally viewed as an inert metabolic end-product of purine catabolism, functions as a potent danger-associated molecular pattern (DAMP) at supraphysiological levels, driving cellular stress and inflammatory cascades.

```
[Hyperuricemia / Elevated Urate]
│
▼
Pancreatic Acinar Cells & Intestinal Mucosa
│
├──────► Increased Intracellular ROS ──► Mitochondrial & ER Stress
│
├──────► Upregulation of CNR1 Expression
│ │
│ ▼
│ p38 MAPK / NF-κB Axis ──► NLRP3 Inflammasome Assembly
│ │
│ ▼
│ IL-1β & IL-18 Secretion
│
└──────► Intestinal Tight Junction Degradation (ZO-1 / Occludin)
│
▼
Gut Dysbiosis & LPS Translocation ──► Exacerbated Pancreatic Necrosis
```

Molecular Pathways and CNR1 Upregulation

At the cellular level, elevated extracellular urate penetrates acinar cells via specific solute carriers, triggering intracellular oxidative stress through NADPH oxidase activation and mitochondrial electron transport chain decoupling. Hyperuricemic environments induce direct transcriptional upregulation of *CNR1*, the gene encoding Cannabinoid Receptor 1. CNR1, a G-protein-coupled receptor, acts as a pivotal node in inflammatory signaling. Ligand activation of CNR1 stimulates the p38 mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB) pathways. This axis promotes the assembly of the NLRP3 inflammasome complex, facilitating the proteolytic cleavage of pro-caspase-1 into active caspase-1 and the subsequent maturation and release of pro-inflammatory cytokines, specifically interleukin-1 beta (IL-1β) and interleukin-18 (IL-18).

Organelle Dysfunction and Acinar Cell Death

The convergence of hyperuricemia and CNR1 signaling induces profound organellar damage within pancreatic acinar cells:

Mitochondrial Dysfunction: Loss of mitochondrial membrane potential ($\Delta\Psi_m$), opening of the mitochondrial permeability transition pore (mPTP), and impaired ATP synthesis accelerate premature intracellular zymogen activation (trypsinogen-to-trypsin conversion).

Endoplasmic Reticulum (ER) Stress: Sustained ROS accumulation triggers the unfolded protein response (UPR) via PERK and IRE1α pathways, shifting acinar cell survival mechanisms toward apoptotic and necroptotic cell death cascades (mediated by RIPK1/RIPK3/MLKL).

Dysregulation of the Gut-Pancreas Axis

Hyperuricemia-mediated CNR1 activation extends beyond the pancreas to the intestinal epithelium. Elevated systemic urate alters the gut luminal microenvironment, driving dysbiosis characterized by a reduction in short-chain fatty acid (SCFA)-producing taxa (e.g., *Faecalibacterium prausnitzii*) and an expansion of pathobionts. Furthermore, signaling through CNR1 degrades epithelial tight junction architecture by downregulating Zonula Occludens-1 (ZO-1) and Occludin expression. The resulting intestinal hyperpermeability enables the translocation of lipopolysaccharide (LPS) and microbial metabolites into the portal bloodstream, establishing a feed-forward inflammatory circuit that amplifies pancreatic necrosis and systemic inflammation.

Sex-Dimorphic Regulation & Translational Implications

Integrating sex-and-gender-based analysis (SGBA) into metabolic pancreatitis research reveals distinct pathophysiological profiles between female and male biology. Biological sex profoundly modulates uric acid homeostasis, endocannabinoid signaling tone, and gut microbiome composition.

1. Hormonal Regulation of Urate Transporters and CNR1 Signaling:
Premenopausal females exhibit significantly lower baseline serum uric acid concentrations than age-matched males. This protective phenomenon is driven by 17β-estradiol, which downregulates renal tubular urate reabsorption transporters—specifically URAT1 (SLC22A12) and GLUT9 (SLC2A9)—and upregulates urate excretion mechanisms. Furthermore, estrogenic signaling represses CNR1 expression in visceral and parenchymal tissues via estrogen receptor alpha (ERα)-mediated transcriptional interference, rendering female acinar cells less sensitive to hyperuricemia-induced NLRP3 activation. Conversely, high androgen levels in males correlate with elevated URAT1 expression, higher baseline serum urate, and enhanced CNR1-mediated inflammatory tone.

2. Microbial and Metabolic Dimorphism Along the Gut-Pancreas Axis:
Sex differences significantly influence gut microbial resilience against hyperuricemic stress. The female gastrointestinal tract demonstrates higher baseline abundance of mucin-degrading and barrier-protective organisms, such as *Akkermansia muciniphila*, and higher localized SCFA concentration. This microbial architecture cushions against urate-induced tight junction degradation. In contrast, male models subjected to hyperuricemia exhibit rapid loss of intestinal mucosal integrity, pronounced LPS translocation, and severe secondary pancreatic necrosis, highlighting a sex-specific vulnerability in the gut-pancreas barrier.

3. Precision Therapeutics and Targeted Pharmacological Modulation:
Translating these insights into clinical practice necessitates sex-stratified therapeutic strategies:
* CNR1 Antagonism: Peripheral-restricted CNR1 inverse agonists or neutral antagonists represent promising candidates to break the hyperuricemia-inflammation cycle without inducing central nervous system adverse effects.
* Urate-Lowering Therapy (ULT): Early administration of xanthine oxidase inhibitors (e.g., Febuxostat) during acute AP flares may reduce acinar ROS generation and prevent gut barrier breakdown, with dosing algorithms tailored to sex-specific renal clearance rates.
* Targeted Biomarker Panels: Patient stratification should incorporate baseline serum urate, circulating endocannabinoids (e.g., anandamide, 2-AG), and serum LPS levels to identify individuals who will benefit most from combined ULT and CNR1-targeted therapies.

Conclusions & Clinical Outlook

The identification of hyperuricemia as a pathogenic driver of acute pancreatitis operating through CNR1 activation and gut-pancreas axis disruption marks a major conceptual advance in precision gastroenterology. Hyperuricemia acts not merely as a passive biomarker but as an active mediator of organelle dysfunction, acinar necrosis, and intestinal barrier failure. Incorporating sex-and-gender-based analysis reveals that estrogen-mediated regulation of urate transporters and endocannabinoid signaling offers endogenously higher resilience in females, whereas males face an elevated risk of severe, urate-driven pancreatitis exacerbations. Future translational endeavors must prioritize multi-center clinical trials that evaluate peripheral CNR1 inhibitors and urate-lowering agents using sex-stratified cohorts to establish personalized, high-efficacy therapeutic protocols.

Key Insights

Molecular Mechanism: Hyperuricemia directly upregulates CNR1 expression in pancreatic acinar cells, driving ROS-dependent p38 MAPK/NF-κB signaling and NLRP3 inflammasome activation.

Gut-Pancreas Axis Disruption: Elevated urate induces gut dysbiosis and degrades tight junction proteins (ZO-1, Occludin), permitting LPS translocation that intensifies pancreatic necrosis.

Sex-Dimorphic Vulnerability: 17β-estradiol protects against urate-driven AP by repressing renal URAT1/GLUT9 transporters and dampening tissue CNR1 expression, underscoring the necessity of sex-informed therapeutic strategies.

References

1. Zhang, L., Wang, Y., & Chen, R. (2023). Hyperuricemia drives acinar cell injury and NLRP3 inflammasome activation via endocannabinoid receptor 1 in acute pancreatitis. *Pancreatology*, 23(4), 412–421. https://doi.org/10.1016/j.pan.2023.03.008
2. Liu, X., Sun, H., & Zhao, M. (2022). Sex differences in uric acid homeostasis and renal transporter regulation: Implications for metabolic diseases. *Frontiers in Endocrinology*, 13, 892147. https://doi.org/10.3389/fendo.2022.892147
3. Xu, J., Liang, C., & Tan, Y. (2024). Multi-omics profiling reveals gut-pancreas axis dysfunction and microbial endotoxemia in hyperuricemia-aggravated severe acute pancreatitis. *Gut Microbes*, 16(1), 2315601. https://doi.org/10.1080/19490976.2024.2315601